Last reviewed · How we verify

Blood samples for the analysis of sildenafil in plasma

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · FDA-approved active Small molecule Quality 0/100

Blood samples for the analysis of sildenafil in plasma is a Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently FDA-approved.

At a glance

Generic nameBlood samples for the analysis of sildenafil in plasma
SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Blood samples for the analysis of sildenafil in plasma

What is Blood samples for the analysis of sildenafil in plasma?

Blood samples for the analysis of sildenafil in plasma is a Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Who makes Blood samples for the analysis of sildenafil in plasma?

Blood samples for the analysis of sildenafil in plasma is developed and marketed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (see full Pfizer's Upjohn has merged with Mylan to form Viatris Inc. pipeline at /company/pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc).

What development phase is Blood samples for the analysis of sildenafil in plasma in?

Blood samples for the analysis of sildenafil in plasma is FDA-approved (marketed).

Related